Roundup: MedStar, Capital One, USEC
The afternoon roundup, from staff and wire reports:
*MedStar Health of Columbia is teaming up with Rite Aid and Consumer Health Services to provide walk-in health clinics in some Rite Aid stores. Four stores in the Baltimore and Washington regions this summer will get the MedStar PromptCare clinics, which will provide services without an appointment. Physicians will provide screenings and vaccinations, as well as treatment for common illnesses or minor injuries.
MedStar Health, a regional hospital and health care provider, will be responsible for clinical oversight and securing access to follow-up specialty and acute medical services. Customers can pay by cash, credit card or insurance copay.
*Mark Wattles, who owns 6.5 percent of Circuit City, said he would meet with the Richmond chain's lead director, Mikael Salovaara, on Friday. Wattles is seeking to replace the chief executive and board of the consumer-electronics retailer, which is scheduled to report earnings tomorrow.
*Gannett named Kate Marymont, executive editor and vice president of the News-Press in Fort Myers, Fla., the vice president/Information Center content in its U.S. Community Publishing Division. It also named Jennifer Carroll, vice president of new media content, as vice president of digital content for Gannett Digital.
*Capital One of McLean said it would cut as many as 750 jobs in Britain, about 40 percent of its workforce in that country. Most of the jobs will move to other countries, the company said.
*Under Armour got a five-year deal from the University of Utah to be its football team's apparel and footwear outfitter. Financial terms were not disclosed.
*Analysts put out conflicting reports on Fannie Mae of the District and Freddie Mac of McLean, with Goldman Sachs saying shares will tumble to $16 or less and Lehman Brothers saying they'll go to $45 or more.
Shares of Fannie Mae closed today at $29, down almost 3 percent, and shares of Freddie Mac closed at $25.46, down 4.3 percent.
*Emergent BioSolutions chief executive said in an interview with Bloomberg News that the company may double its revenue by the end of 2010. Fuad El-Hibri, head of the Rockville biotech, is developing an anthrax treatment; it already has an anthrax vaccine, whose sales it is looking to boost through the first-responder market.
Emergent BioSolutions is the seventh-best performer in the Russell 2000 Index.
*A Jeffries & Co. analyst boosted his estimate of 2008 earnings for Bethesda-based USEC to 25 cents a share from 20 cents. He also raised his 2009 EPS estimate foto 65 cents from 50 cents.
"Rising uranium ... prices and elevated energy prices provide an attractive backdrop for operational improvements at USEC, particularly given conservative Street expectations on competitor behavior and project execution," Laurence Alexander wrote.
Please email us to report offensive comments.
The comments to this entry are closed.